Predictive Impact of PD-L1 expression for anti-tumor activity of osimertinib in patients with T790M mutated non-small cell lung cancer
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2018 Status changed from not yet recruiting to recruiting.
- 20 Apr 2017 New trial record